AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04163354 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glass ionomer sealant (GIS)
Description: Glass ionomer sealants (GIS) is applied using the finger pressure technique described in the WHO manual for atraumatic restorative treatment (ART) (Frencken et al.; 1997). The primary second molars are cleaned by applying GC cavity conditioner with micro-applicator for 10-15 seconds, then clean with wet cotton pellets for several times. The surface will be dried with cotton pellets. GIS (GC Fuji VII) is mixed in standardized proportion with an amalgamator, then applied to the occlusal surface and slightly overfilled. A gloved finger with petroleum jelly will be used to push and rub the materials into the pits and fissures, and removing the excess. GIS will be covered and protected by a layer of petroleum jelly (Vaseline ®).
Study NCT03029832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOXR0916
Description: MOXR0916, 300 milligram (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle.
Study NCT03029832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab, 1200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle.
Study NCT03682263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full Service
Description: Receive Individual Placement and Support (IPS) model of employment services, behavioral health services, care management services, and Medication Management Support provided by a Nurse Care Coordinator (NCC).
Study NCT03682263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic Service
Description: Receive Individual Placement and Support (IPS) model of employment services, behavioral health services, and care management services.
Study NCT05780268 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3819253
Description: LY3819253 is a neutralizing immunoglobulin G (IgG)-1 monoclonal antibody (mAb) to the receptor binding domain (RBD) of the S protein of SARS-CoV-2
Study NCT05780268 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially available 0.9% sodium chloride solution
Study NCT05780268 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Antiviral agent
Study NCT05780268 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Remdesivir
Description: Antiviral agent
Study NCT03986372 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platlet-rich plasma
Description: Multiple Platlet-rich plasma injection.
Study NCT02712827 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Progrip
Description: Self-fixating mesh
Study NCT02712827 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Progrip
Description: Non self-fixating mesh with the use of glue
Study NCT04285840 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Venous ACT
Description: Matched/paired venous ACT samples will be drawn at the same time as arterial ACT samples to compare the results agreement between venous and arterial ACTs. Subjects undergoing atrial fibrillation ablations will continue to have Heparin dosed on the arterial ACT sample results only per the standard of care. Heparin will not be administered based on venous ACT levels obtained during this study.
Study NCT01863654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg chewable tablets
Description: Reference product
Study NCT01863654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg chewable tablets
Description: Test product
Study NCT01642732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Everolimus, lupron, bicalutamide, and radiation
Description: Everolimus - there are five dose levels (2.5mg. every 48 hrs.,2.5mg./day, 5mg./day, 7.5mg./day, and 10mg./day) based on the initial expectations of toxicity and the incidence of toxicity of subjects already treated. Subjects will be on one dose level throughout the study. Subjects will receive everolimus starting on study day 1.~Radiation therapy will start on day 60-70 (44 treatments, at 5 treatments a week for a little longer than 8 weeks).~Bicalutamide (50 mg. tablets daily) will begin on study day 10-14, approximately 2 months prior to Radiation Therapy.~Lupron injections will begin on study day 15 to 25, approximately 2 months prior to Radiation Therapy. The typical dose schedule is either one injection (22.5 mg. dose)every 3 months for a total of 8 injections or one injection (30 mg. dose) every 4 months for a total of 6 injections.~Radiation, bicalutamide, and everolimus will end between study day 120-130. Lupron will end at 24 months on study.
Study NCT01397734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide
Description: 0.15mg/kg/day Arsenic trioxide given IV on days 1-5 of the cycle.
Study NCT03029832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab, 1200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle.
Study NCT02467998 — intervention group
Intervention type: DEVICE
Intervention: NPWT
Description: SVAP polyurethane foam, RENASYS foam, RENASYS gauze, AMD gauze, VAC white sponge, VAC black sponge, applied with various NPWT devices, in addition to various dressings to protect wound edges
Study NCT01166048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Duloxetine
Description: Patients will receive 120mg of Duloxetine for the duration of 2 weeks after a dosage titration of 2 weeks according to the following scheme: (p=placebo)~day: 1 2 3 4 5 6 7: p-30mg p-30mg p-30mg p-30 mg p-30mg p-30mg p-60mg~day: 8 9 10 11 12 13 14: p-60 mg p-60 mg p-60mg p-60mg p-60mg p-60mg 60-60mg
Study NCT01166048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: 2 weeks of titration of duloxetine to 120mg, (1-0-1), 2 weeks of continuation on 120mg/day.
Study NCT01166048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Duloxetine
Description: 2 weeks of titration of duloxetine to 120mg, (1-0-1), 2 weeks of continuation on 120mg/day.
Study NCT01382641 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hoya AF-1 IOL
Description: The patients will be assessed for three months
Study NCT01382641 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Revital vision
Description: The patients will be assessed for three months.
Study NCT03471325 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plaque disclosed with air flow
Description: air polishing with prior plaque disclosing
Study NCT04395950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-05221304
Description: PF-05221304 10 mg daily (two 5mg tablets daily in the morning for 6 weeks)
Study NCT04395950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo two tablets daily in the morning for 6 weeks
Study NCT00667173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-115
Description: Topical application for 12 weeks
Study NCT02695797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IVIG
Description: IVIG (400mg/kg/day for 5 days) with oral prednisolone (60mg for 5days, than decrease by 10 mg every 2 day)
Study NCT02695797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: IVIG (400mg/kg/day for 5 days) with oral prednisolone (60mg for 5days, than decrease by 10 mg every 2 day)
Study NCT05634772 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dormia basket
Description: Use of dormia basket in management of proximal stent migration
Study NCT05634772 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extraction biliary ballon
Description: Use of extraction biliary balloon in management of proximal stent migration
Study NCT03471325 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plaque disclosed with rubber cup
Description: rubber cup polishing with prior plaque disclosing
Study NCT00667173 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical application for 12 weeks
Study NCT03471325 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non plaque disclosed air flow
Description: air polishing with no prior plaque disclosing
Study NCT03471325 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Non plaque disclosed rubber cup
Description: rubber cup polishing with no prior plaque disclosing
Study NCT00842933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: Cessation of corticosteroids 24 hours after cessation of vasopressors
Study NCT00205907 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BLVR Hydrogel
Description: 10 mL BLVR Hydrogel
Study NCT03505398 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microperimetry
Description: define the retinal fixation point and the differential sensitivity threshold of the retina.
Study NCT03505398 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: microperimetry
Description: define the retinal fixation point and the differential sensitivity threshold of the retina.
Study NCT03505398 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: visual acuity
Description: using ETDRS scales
Study NCT03505398 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: visual acuity
Description: using ETDRS scales
Study NCT00842933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Administer daily for 7 days after diagnosis of acute adrenal insufficiency during septic shock
Study NCT00323284 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iStent plus Cataract Surgery
Description: ab interno trabecular bypass stent surgery
Study NCT00323284 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery only
Description: Cataract surgery only
Study NCT03606278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured debriefing assisted by video
Description: In the structured debriefing assisted by video, the process was based on the immediate review of the video, stopping and rewinding the recording as required. The debriefing session was conducted in the debriefing room of the simulation laboratory with an assigned time of 15 minutes. Each session was developed in three phases. The first phase, descriptive, in which each participant was encouraged to recount what they had lived and experienced, clarifying how the events unfolded, verifying the appropriate decisions and the errors committed in the scenario and the ways they could have solved them and corrected them. The second phase, analytical, the participant reflected on what occurred in the scenario, commenting on how their feelings were involved in the development of the case. The third phase, application or transference, in which the group was encouraged to draw conclusions from what had occurred, realizing an application of this experience in a real-life.
Study NCT03606278 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Structured oral debriefing
Description: In the structured oral debriefing, the process was based by the mental search of their memories of what occurred. The debriefing session was conducted in the debriefing room of the simulation laboratory with an assigned time of 15 minutes. Each session was developed in three phases. The first phase, descriptive, in which each participant was encouraged to recount what they had lived and experienced, clarifying how the events unfolded, verifying the appropriate decisions and the errors committed in the scenario and the ways they could have solved them and corrected them. The second phase, analytical, the participant reflected on what occurred in the scenario, commenting on how their feelings were involved in the development of the case. The third phase, application or transference, in which the group was encouraged to draw conclusions from what had occurred, realizing an application of this experience in a real-life.
Study NCT01796886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pupillometry data
Study NCT00115128 — intervention group
Intervention type: DRUG
Intervention: filgrastim
Description: Normal donors being treated with filgrastim for PBPC mobilization and collection
Study NCT04000386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: zinc oxide nanoparticles coated socks
Description: zinc oxide nanoparticles coated socks were given to subjects for 2 weeks
Study NCT04000386 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo socks
Description: placebo socks were given to subjects for 2 weeks
Study NCT02115308 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Regadenoson
Description: Regadenoson injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging.
Study NCT03550781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone, cyclophosphamide
Description: Prednisone 0.5mg/(kg•d) and/or cyclophosphamide 2mg/kg
Study NCT03292354 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Contrast media administration
Description: All patients will receive contrast media with a concentration of 300 mg I/mL (Iopromide 300). The flowrate and volume will be calculated with help of the different formulas belonging to the three different arms.
Study NCT03544580 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate implant with dentine chips
Description: Using dentin chips
Study NCT03544580 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional immediate implant
Description: using xenograft
Study NCT01575613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine combination
Description: Focal screening and treatment in all households in malaria hotspots prior to the peak transmission season. Screening of a sentinel age group by rapid diagnostic tests; all parasitaemic individuals and household members of parasitaemic individuals will be treated.
Study NCT01575613 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacillus thuringiensis
Description: Treatment of all waterbodies within hotspots with Bti or Bs on weekly basis
Study NCT01575613 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Long lasting insecticide treated net (LLINs)
Description: Distribution of LLINs in all households in malaria hotspots; instruction about correct use.
Study NCT01575613 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Indoor Residual Spraying (IRS)
Description: 6-monthly IRS with deltamethrin in all households malaria hotspots.
Study NCT04623957 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ForgTin©
Description: The device is clamped behind the ear via two connected temple parts that pressed together around the connecting axis until an individual perfect wearing comfort is achieved. The pressure is adjusted so that the wearing of ForgTin© is barely noticed at all and may be changed at any time.~The aim is a slight pressure stimulation of clearly defined points behind the ear - thus wearing ForgTin© leads to a minimization of individual tinnitus noises.
Study NCT03580330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth intervention
Description: Individual in the intervention group receive a weekly educational health SMS for the intervention period of 1 year. SMS content covered different health themes providing health information on lifestyle, dietary habits, body weight, smoking, medications, importance of compliance, as well as symptoms and self-management of HTN and diabetes. Community individuals who were diagnosed and were receiving necessary care previous to the investigator's intervention were sent weekly informative health SMS, as well as customized SMSs reminders to follow up on their scheduled medical appointments (eg, to check their HbA1c levels and have their annual foot or eye exams).
Study NCT02337387 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blosozumab
Description: Administered SC
Study NCT02337387 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT00358449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mepolizumab
Description: Participants received mepolizumab 0.55 milligrams (mg)/kilogram (kg), 2.5 mg/kg , or 10 mg/kg by intravenous (IV) infusion for 30 minutes on Day 1, Week 4 and Week 8.
Study NCT03878485 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRIdian Linac System from ViewRay
Description: * 0.35T MRI combined with a linear accelerator~* This device will be used for the Stereotactic MRI-guided Adaptive Radiotherapy
Study NCT03878485 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic MRI-guided Adaptive Radiotherapy
Description: -The MR-linac will be delivering the radiation
Study NCT00667706 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic operation Sleeve Gastrectomy
Description: Laparoscopic Sleeve Gastrectomy will be performed employing a 5-6 trocar technique, and includes gastric resection starting 4-5 cm proximal to the pylorus, using a 38 fr. Bougie and endoscopic stapler with blue and green load.
Study NCT00667706 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic operation Roux-en-Y Gastric bypass
Description: Divided LRYGB will employ 5-7 trocars technique, and includes stapled jejunojejunostomy 30-50 cm distal to the Treitz ligament, gastric pouch of 20 cc., and antecolic, antegastric gastrojejunal anastomosis, either two layered hand-sawn, GIA, or EEA-25 -stapled, at surgeons preference. The length of the Roux limb will be 100 centimeters or 150 centimeters in patients with BMI of \<50, and >50, respectively.
Study NCT01642212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Budesonide Suspension (MB-9)
Description: OBS suspension to be taken bid over a 16 week course of double blind therapy and OBS suspension to be taken qd to bid during a 24 week optional open label extension period
Study NCT01642212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01137214 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive positive pressure ventilator
Description: All patients will initially be treated with CPAP for 12 weeks as part of usual clinical treatment for sleep apnea. A sleep study will be conducted after this and prior to randomization into the study. If this repeat sleep study demonstrates persistent central sleep apnea, patients will be randomized into 2 study groups. Group 1 - CPAP for 24 weeks. Group 2 - first 12 weeks CPAP (Continuous Positive Airway Pressure. Next 12 weeks - (ASV) Adaptive Servo ventilation. If the treatment is not working well at 12 weeks the participant/patients have the option of switching to the alternate treatment. Patients will be notified if they are to be switched to ASV. Participants will be asked to fill in the Epworth Sleepiness Score Questionnaire and Sleep Apnea Quality of Life Index form at 12 and 24 weeks.
Study NCT01106001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: The treatment group received 150mg of levobupivicaine in 60mls of 0.9% saline. This was injected intra-operatively through the medial and anterior capsular spaces in the region of the obturator and femoral nerves and also around the short rotators and gluteus maximus in the region of the inferior and superior gluteal nerves. The timing of this was after insertion of the acetabular component. 10mls was then infiltrated around the tensor fascia lata and subcutaneously prior to closing the wound.
Study NCT01708824 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary
Description: Dietary intervention to meet the target of~1. \<5 servings of red/processed meat weekly; \<2 servings would be processed meat~2. 2 servings of refined grains daily
Study NCT01708824 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Physical activity intervention with the following targets:~1. General health target - 30 minutes of moderate-to-vigorous physical activity (MVPA) 5 days per week (i.e. 10 MET-hours/week);~2. Cancer outcome target - 60 minutes of MVPA 5 days per week (i.e. 18-20 MET-hours/week)
Study NCT00816569 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthokeratology contact lenses
Description: Wearing Orthokeratology lens in one eye of a keratoconus patient
Study NCT02331394 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chinese herbs formula: Shu Yu Wan
Description: The patients will be offered the choice of taking the CH formula in capsules or sachets and given instructions about recommendations to improve palatability. The formula should be taken with meals 3 times a day (each dose is either 1 sachet or 4 capsules) for six-weeks.
Study NCT04395417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: Patients were infiltrated with injection single dose 30 mg/2 ml 1500 kilodalton high molecular weight hyaluronic acid at the lateral epicondyle according to the standard technique.
Study NCT04395417 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolotherapy
Description: Patients were infiltrated with 5cc of dextrose 15% at the lateral epicondyle according to the standard technique. For solution, 1 cc 2% lidocaine, 5 cc 30% hypertonic dextrose and 4 cc 0.9 % isotonic were used.
Study NCT00771485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FM-602
Description: Study of Efficacy of Bowel Preparation Before Colonoscopy
Study NCT00771485 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Marketed Bowel Cleanser
Description: Marketed bowel cleanser